Hematology

Surveillance and Safety: Managing Iron Overload and Chelation

At a Glance

Iron overload in microcytic anemia can silently damage the liver and heart, so regular liver and cardiac MRI, ferritin checks, and medication-specific monitoring are essential. Cardiac symptoms or fever while taking deferiprone need urgent medical attention.

Living with a rare iron-loading anemia requires a shift in how you think about your health. Because your body cannot properly regulate iron, your organs—especially your heart and liver—are at risk of silent damage ^[1]. Effective management depends on an individualized schedule of “look-ins” to ensure iron levels stay within a safe range and that medications are not causing unexpected side effects.

Recognizing Emergency “Red Flags”

While most iron loading happens slowly over years, iron-overload cardiomyopathy (heart muscle disease caused by iron) can cause serious complications ^[2]^[3].

Seek emergency medical care immediately if you experience:

New severe chest pain ^[4].
Severe breathlessness at rest or difficulty breathing when lying flat (orthopnea) ^[4].
Rapid swelling in your legs, ankles, or abdomen ^[4].
Sustained palpitations, a racing heart, or a feeling that your heart is “skipping” ^[5].
Sustained fainting (syncope) or near-fainting ^[4].

These symptoms can indicate heart failure or dangerous heart rhythms (arrhythmias) ^[5]^[2]. In the emergency room, ensure the team knows you have a history of iron overload, though acute symptoms will be assessed based on standard vital signs and ECGs ^[6]. Not every symptom is necessarily caused by iron.

The Surveillance Schedule

To prevent emergencies, you and your care team will follow a routine monitoring plan. Ferritin alone cannot tell the whole story ^[7].

Individualized MRI Monitoring

Standard care typically includes a specialized MRI on an individualized schedule, often once a year, to measure organ iron directly ^[8]^[3].

Liver Iron Concentration (LIC): Your goal is usually to keep your LIC below a specific risk band (such as 7 mg/g of dry weight), though lower is often preferred ^[9]. An LIC above 8-10 mg/g is associated with a higher risk of complications ^[10].
Cardiac T2*: This separate technique measures iron in your heart muscle. A result above 20 ms is considered lower risk. If your result drops below 10 ms, it indicates severe iron loading and requires an urgent review of your treatment plan ^[7]^[9].

Monthly Blood Work

Between MRIs, your doctor will likely check your ferritin levels regularly ^[8]. Ferritin acts as a “trend-line” helping determine if you are absorbing iron faster than your current treatment removes it ^[11].

Chelation Safety and Monitoring

The medications used to remove iron (chelators) are potent and require their own dedicated safety checks to protect your kidneys, liver, and immune system.

Deferasirox (Exjade/Jadenu) Safety

If you take deferasirox, your monitoring focuses on your kidneys and liver. This drug can cause direct irritation to the kidneys or gastrointestinal bleeding ^[12]^[13].

Renal Checks: You should have baseline and serial serum creatinine (or eGFR) and urine protein checked regularly ^[14]^[15].
Liver and GI Checks: Liver enzymes (ALT/AST) should be checked regularly ^[16]^[17].
Warning Signs: Significant enzyme elevations or warning signs like reduced urine output, severe abdominal pain, GI bleeding, severe rash, jaundice, or hearing/vision changes require promptly contacting your doctor, who may pause the medication.

Deferiprone (Ferriprox) Safety

The most critical safety rule for deferiprone involves tracking your white blood cells ^[18]. This medication carries a risk of agranulocytosis, a rare but serious condition where your infection-fighting cells drop to dangerously low levels ^[19].

ANC Monitoring: You must have an Absolute Neutrophil Count (ANC) checked regularly, often weekly during the first year, though schedules differ by product and jurisdiction ^[18].
The Fever Rule: If you develop a fever, sore throat, or mouth ulcers, you must contact your prescribing team immediately for an urgent ANC according to your written plan. Do not wait for a scheduled test or independently decide to stop or restart the drug ^[18]^[19].

By staying consistent with your individualized monitoring, you can catch iron buildup before it affects your heart and ensure your treatments are working safely.

Common questions in this guide

How often should MRI check iron in my liver and heart?

The schedule is individualized, but specialized MRI monitoring is often done about once a year. Liver iron concentration, or LIC, estimates iron stored in the liver, while cardiac T2* measures iron in the heart; the results help your team adjust chelation.

What does a cardiac T2* result say about my risk?

A cardiac T2* above 20 milliseconds is generally a lower-risk result. A value below 10 milliseconds indicates severe heart iron loading and should prompt an urgent review of the treatment plan.

Why do I need ferritin tests if I already have MRI scans?

Ferritin is useful as a regular trend line showing whether iron is building up faster than treatment removes it. Ferritin alone does not show the full amount of iron in the liver or heart, so it is interpreted with organ MRI results.

What monitoring is needed with deferasirox?

Deferasirox usually requires regular checks of kidney function, urine protein, and liver enzymes. Reduced urine, severe abdominal pain, gastrointestinal bleeding, a severe rash, jaundice, or hearing or vision changes should be reported promptly to the prescribing clinician.

What should I do if I develop a fever while taking deferiprone?

Contact your prescribing team immediately for an urgent absolute neutrophil count, or ANC, especially if you also have a sore throat or mouth ulcers. Do not wait for the next scheduled test or stop and restart the medicine on your own; follow your written plan.

Which symptoms of iron overload need emergency care?

Seek emergency care for new severe chest pain, severe breathlessness at rest or when lying flat, rapidly worsening swelling, sustained palpitations, or fainting or near-fainting. Tell the emergency team that you have iron overload, although they will assess the symptoms using standard vital signs and heart testing.

Get notified when new evidence is published on Microcytic anemia with liver iron overload.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References (19)

1
Inherited iron overload disorders.
Piperno A, Pelucchi S, Mariani R
Translational gastroenterology and hepatology 2020; (5()):25 doi:10.21037/tgh.2019.11.15.
PMID: 32258529
2
Severe iron overload cardiomyopathy manifested as acute myopericarditis: A case report.
Kosum P, Theerasuwipakorn N, Wicheantawatchai A, et al.
Radiology case reports 2024; (19(1)):290-295 doi:10.1016/j.radcr.2023.10.020.
PMID: 38028286
3
Cardiovascular magnetic resonance in β-thalassemia major: beyond T2.
Meloni A, Saba L, Cademartiri F, et al.
La Radiologia medica 2024; (129(12)):1812-1822 doi:10.1007/s11547-024-01916-6.
PMID: 39511065
4
Acute-Onset Iron Overload Cardiomyopathy in Diamond-Blackfan Anaemia: A Case Report of Rapid Ejection Fraction Decline.
Waddon J, Hawkins C, Toquero M, et al.
Cureus 2026; (18(9)):e116110 doi:10.7759/cureus.116110.
PMID: 42865678
5
Cardiac complications in thalassemia major.
Auger D, Pennell DJ
Annals of the New York Academy of Sciences 2016; (1368(1)):56-64 doi:10.1111/nyas.13026.
PMID: 26963698
6
Beyond the blood: A practical guide to thalassemia care in the emergency department.
Mufarrij A, Hodroj MH, Charbel N, et al.
Blood reviews 2025; (74()):101327 doi:10.1016/j.blre.2025.101327.
PMID: 40769855
7
Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
Karakas Z, Yilmaz Y, Bayramoglu Z, et al.
La Radiologia medica 2018; (123(8)):572-576 doi:10.1007/s11547-018-0889-0.
PMID: 29663188
8
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload.
Origa R, Cinus M, Pilia MP, et al.
Journal of clinical medicine 2022; (11(7)) doi:10.3390/jcm11072010.
PMID: 35407617
9
Modern management of iron overload in thalassemia major patients guided by MRI techniques: real-world data from a long-term cohort study.
Bayraktaroglu S, Karadas N, Onen S, et al.
Annals of hematology 2022; (101(3)):521-529 doi:10.1007/s00277-021-04748-w.
PMID: 34985558
10
Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study.
Musallam KM, Barella S, Origa R, et al.
Annals of hematology 2024; (103(7)):2283-2297 doi:10.1007/s00277-024-05715-x.
PMID: 38503936
11
Gonadal Hormones in Adolescent Females with β-Thalassemia in Relation to Iron Load.
Hagag AA, Badraia IM, Elfarargy MS, Abo El-Enein AM
Endocrine, metabolic & immune disorders drug targets 2016; (16(2)):148-153 doi:10.2174/1871530316666160506150516.
PMID: 27150601
12
Deferasirox-associated Fanconi syndrome in adult patients with transfusional iron overload.
Yui JC, Geara A, Sayani F
Vox sanguinis 2021; (116(7)):793-797 doi:10.1111/vox.13064.
PMID: 33529394
13
Effects of deferasirox dose and decreasing serum ferritin concentrations on kidney function in paediatric patients: an analysis of clinical laboratory data from pooled clinical studies.
Bird ST, Swain RS, Tian F, et al.
The Lancet. Child & adolescent health 2019; (3(1)):15-22 doi:10.1016/S2352-4642(18)30335-3.
PMID: 30455109
14
Renal Function in Patients with Thalassemia Major Receiving Exjade® Dispersible Tablets and a New Film-coated Tablet Formulation of Deferasirox (Nanojade®).
Falahati V, Ghasemi A, Safari MR, et al.
Advanced biomedical research 2022; (11()):84 doi:10.4103/abr.abr_89_21.
PMID: 36518868
15
The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.
Bayhan T, Ünal Ş, Ünlü O, et al.
Hematology (Amsterdam, Netherlands) 2017; (22(4)):248-251 doi:10.1080/10245332.2016.1252004.
PMID: 27809710
16
International sentinel site surveillance of patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.
El-Beshlawy A, Inusa B, Beneitez Pastor D, et al.
Hematology (Amsterdam, Netherlands) 2019; (24(1)):238-246 doi:10.1080/16078454.2018.1558758.
PMID: 30558524
17
Acute Liver Failure During Deferasirox Chelation: A Toxicity Worth Considering.
Menaker N, Halligan K, Shur N, et al.
Journal of pediatric hematology/oncology 2017; (39(3)):217-222 doi:10.1097/MPH.0000000000000786.
PMID: 28221265
18
Deferiprone-induced agranulocytosis: 20 years of clinical observations.
Tricta F, Uetrecht J, Galanello R, et al.
American journal of hematology 2016; (91(10)):1026-31 doi:10.1002/ajh.24479.
PMID: 27415835
19
Rates of severe neutropenia and infection risk in patients treated with deferiprone: 28 years of data.
Badawy SM, Palmblad J, Tricta F, et al.
Blood advances 2024; (8(21)):5641-5649 doi:10.1182/bloodadvances.2023012316.
PMID: 38640437

This page is for informational purposes only and is not medical advice. Your hematology team should individualize MRI, blood-test, and chelation monitoring for your health needs.